Alnylam Pharmaceuticals reports Q3 2024 earnings and outlines future plans

Alnylam Pharmaceuticals held its Q3 2024 earnings call on October 31, 2024. The call featured key executives discussing the company's performance and future plans. Participants included the CEO, Chief Commercial Officer, Chief Medical Officer, and Chief Financial Officer. During the call, the executives provided updates on commercial progress, clinical pipeline developments, and financial results. They also outlined upcoming milestones for the company. The call was recorded, and a question-and-answer session was included for participants to engage with the executives.